|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have shown that the combination of crizotinib and an inhibitor of downstream signaling induces a favorable response in transgenic mice bearing ALK(F1174L)/MYCN-positive neuroblastoma.
|
25228590 |
2014 |
|
rs863225281
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have shown that the combination of crizotinib and an inhibitor of downstream signaling induces a favorable response in transgenic mice bearing ALK(F1174L)/MYCN-positive neuroblastoma.
|
25228590 |
2014 |
|
rs113994087
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We detected the ALK mutation (F1174C and R1275Q) in 2 (3.7%) of the 54 NB specimens.
|
21940108 |
2011 |
|
rs1057519697
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected the ALK mutation (F1174C and R1275Q) in 2 (3.7%) of the 54 NB specimens.
|
21940108 |
2011 |
|
rs113994087
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using both Sanger and targeted deep sequencing, this study describes the identification of distinct ALK mutations in these paired cell lines, including the rare R1275L mutation, which has not previously been reported in a neuroblastoma cell line.
|
27888620 |
2016 |
|
rs113994087
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To study the contribution of ALK mutations in NB initiation and progression, we reprogrammed fibroblasts from two related NB patients carrying germline mutations in ALK (R1275Q) using non-integrating Sendai virus.
|
30605844 |
2019 |
|
rs113994087
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tumorigenesis in mouse models, and cooperate with MYCN in the oncogenic process.
|
24947326 |
2014 |
|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tumorigenesis in mouse models, and cooperate with MYCN in the oncogenic process.
|
24947326 |
2014 |
|
rs863225281
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The two most frequent mutations, ALK-F1174L and ALK-R1275Q, contribute to NB tumorigenesis in mouse models, and cooperate with MYCN in the oncogenic process.
|
24947326 |
2014 |
|
rs113994087
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most frequent ALK mutations in neuroblastoma cause amino acid substitutions (F1174L and R1275Q) in the intracellular tyrosine kinase domain of the intact ALK receptor.
|
22072639 |
2011 |
|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most frequent ALK mutations in neuroblastoma cause amino acid substitutions (F1174L and R1275Q) in the intracellular tyrosine kinase domain of the intact ALK receptor.
|
22072639 |
2011 |
|
rs863225281
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most frequent ALK mutations in neuroblastoma cause amino acid substitutions (F1174L and R1275Q) in the intracellular tyrosine kinase domain of the intact ALK receptor.
|
22072639 |
2011 |
|
rs113994087
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
|
22932897 |
2012 |
|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
|
21030459 |
2010 |
|
rs863225281
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
|
21030459 |
2010 |
|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Targeted ALK(F1174L) and MYCN coexpression revealed a strong synergism in inducing neuroblastoma with minimal chromosomal aberrations, suggesting that fewer secondary hits are required for tumor induction if both oncoproteins are targeted.
|
22764207 |
2012 |
|
rs863225281
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Targeted ALK(F1174L) and MYCN coexpression revealed a strong synergism in inducing neuroblastoma with minimal chromosomal aberrations, suggesting that fewer secondary hits are required for tumor induction if both oncoproteins are targeted.
|
22764207 |
2012 |
|
rs863225285
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results show that the Y1278S mutant observed in patients with neuroblastoma harbors gain-of-function activity.
|
29084134 |
2017 |
|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intrinsic susceptibility-MRI could thus potentially provide a non-invasive and clinically-exploitable method to help identifying children with MYCN-driven neuroblastoma harboring the ALK(F1174L) mutation at the time of diagnosis.
|
24667968 |
2014 |
|
rs863225281
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intrinsic susceptibility-MRI could thus potentially provide a non-invasive and clinically-exploitable method to help identifying children with MYCN-driven neuroblastoma harboring the ALK(F1174L) mutation at the time of diagnosis.
|
24667968 |
2014 |
|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, lethal neuroblastoma</span> frequently developed in mice co-expressing ALK F1174L and MYCN, even in a genetic background where MYCN alone does not cause overt tumors.
|
31218818 |
2019 |
|
rs863225281
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, lethal neuroblastoma</span> frequently developed in mice co-expressing ALK F1174L and MYCN, even in a genetic background where MYCN alone does not cause overt tumors.
|
31218818 |
2019 |
|
rs863225285
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Herein, we have illustrated the dynamic conformational property of wild-type ALK as well as the kinase activation equilibrium variation induced by two neuroblastoma mutations (R1275Q and Y1278S) and ATP binding by performing enhanced sampling accelerated Molecular Dynamics (aMD) simulations.
|
29638111 |
2018 |
|
rs113994087
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Herein, we have illustrated the dynamic conformational property of wild-type ALK as well as the kinase activation equilibrium variation induced by two neuroblastoma mutations (R1275Q and Y1278S) and ATP binding by performing enhanced sampling accelerated Molecular Dynamics (aMD) simulations.
|
29638111 |
2018 |
|
rs281864719
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we report similar basal patterns of ALK phosphorylation between the neuroblastoma IMR-32 cell line, which expresses only the wild-type receptor (ALK(WT)), and the SH-SY5Y cell line, which exhibits a heterozygous ALK F1174L mutation and expresses both ALK(WT) and ALK(F1174L) receptors.
|
22479414 |
2012 |